Overview
INJ and AKE rarely move in perfect sync. Today’s print ($4.98/$1,853.59) and 24h leaders (AKE) help frame which side currently carries relative strength.
Quick winners
Full comparison
| Metric | INJ | AKE |
|---|---|---|
| Price | $4.98 | $1,853.59 |
| Market Cap | $490.41M | $104.21M |
| FDV | — | — |
| Volume 24h | $2.75M | $48.18M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 251.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | AKE |
|---|---|---|
| 1H | — | — |
| 24H | +1.20% | +6.20% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | AKE |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 67.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Injective shows RSI 49.29 with trend bias neutral, while AKE sits at RSI 49.02 (bearish). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | INJ | AKE |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
AKE
Pros and cons
Pros of Injective
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
Cons of Injective
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
Pros of AKE
- If technical momentum aligns, AKE may outperform on medium-term windows.
- PEPS tracking for AKE still includes AI score and level context for monitoring.
- Diversifying versus Injective with AKE can change portfolio factor exposure.
Cons of AKE
- Relative underperformance versus Injective can persist through entire market regimes.
- Weaker market-cap standing may leave AKE more exposed to liquidity droughts.
- Higher volatility on AKE cuts both ways and demands stricter risk limits.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Injective, while short-term performance leans toward AKE. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
For readers asking which is “better”, the honest answer is conditional. Injective and AKE solve overlapping but not identical market jobs. On-chain and developer fields, when available, add slower-moving context beneath the tape. Missing fundamentals should be treated as unknown, not as zeros. If your thesis is long-term adoption, weight fundamentals and liquidity; if tactical, weight trend/momentum — and always define invalidation.
FAQ
Which is better, Injective or AKE?
“Better” depends on horizon and risk. Injective leads on market cap today, while AKE leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or AKE?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and AKE.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. AKE currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is AKE, but longer windows can disagree.